NEX002

NEX002: sourced facts only. name: "NEX002 is an oral liver-targeted ALK5 inhibitor with low heart exposure for the treatment of liver cancer and other gastrointestinal cancers with liver metastases." [1] target: "In particular, small molecule TGFβ inhibitors targeting ALK5 (TGFβ type 1 receptor) have been limited by mechanism-based heart valve toxicity to low dose and intermittent dosing regimens. NEX002 is an oral liver-targeted ALK5 inhibitor with low heart exposure" [1] developer: "1Nexys Therapeutics, San Diego, CA." [2] stage: "NEX002 has demonstrated activity in several intrahepatic and subcutaneous tumor models, and significantly enhanced the durability of anti-tumor efficacy in combination with lenvatinib" [1] modality: "The compound was designed following drug design principles from known liver-specific drugs, such as the statins." [1]